CM338 for immunoglobulin A kidney disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests CM338 to see if it can help people with immunoglobulin A (IgA) nephropathy, a kidney condition. You may be able to join if you meet age, medication, and health criteria and can follow study safety rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You understand the study and agree by signing the consent form
- If pregnancy is possible for you, you will use reliable birth control during the study
- You did not take another investigational (research) drug in the 30 days before starting this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This trial tests a new medicine called NM8074 for people with IgA nephropathy (a kidney disease). The medicine is given as an infusion and aims to slow down the damage to your kidneys. If you have this condition and meet the health requirements, the trial might help you manage your kidney health.
This study tests an investigational drug called SCTC21C for people with IgA nephropathy, a kidney disease caused by abnormal antibodies. The drug aims to target and reduce these harmful antibodies, which may help slow kidney damage.
This trial tests a new immune cell treatment (CAR-T) for people with certain kidney diseases—IgA nephropathy or membranous nephropathy—that have not improved with standard care. The therapy aims to calm the immune system to protect the kidneys.
This trial is testing whether the drug mycophenolate mofetil can help people whose IgA nephropathy hasn't improved with standard treatments. It aims to reduce protein in the urine and protect kidney function.
This study tests a new drug, MY008211A, for people with a type of kidney disease called IgA nephropathy. The goal is to see if it can reduce protein in the urine and help protect kidney function. You must have had a kidney biopsy confirming the diagnosis and be on stable standard care.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.